Arrowhead Pharmaceuticals, Inc.
177 East Colorado Boulevard,
Suite 700
Pasadena
California
91101
United States
466 articles with Arrowhead Pharmaceuticals, Inc.
-
Arrowhead Pharmaceuticals Reports Fiscal 2022 Second Quarter Results
5/10/2022
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2022.
-
Arrowhead Pharmaceuticals to Participate in Upcoming May 2022 Conferences
5/2/2022
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: TIDES USA 2022: Oligonucleotide and Peptide Therapeutics – May 9-12, 2022.
-
Arrowhead Pharmaceuticals Appoints Victoria Vakiener to Board of Directors
5/2/2022
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the board of directors appointed veteran pharmaceutical industry executive Victoria Vakiener, as an independent director of the company, with a term beginning effective May 2, 2022.
-
A roundup of last week's top clinical trial updates and news.
-
Arrowhead Pharmaceuticals to Host Pulmonary R&D Day
4/27/2022
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a pulmonary research & development (R&D) day to discuss its emerging pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates from 10:00 a.m. to 1:00 p.m. ET on May 26, 2022, in New York City.
-
Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Familial Hypercholesterolemia
4/26/2022
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patients in the Phase 2 GATEWAY clinical study of investigational ARO-ANG3 for the treatment of patients with homozygous familial hypercholesterolemia (HoFH).
-
Arrowhead Pharmaceuticals and Vivo Capital Launch Joint Venture Aimed at Greater China Market
4/25/2022
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has formed a joint venture, Visirna Therapeutics, with Vivo Capital to expand the reach of innovative medicines in Greater China.
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Second Quarter Results
4/20/2022
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 10, 2022, at 4:30 p.m. ET to discuss its financial results for the fiscal 2022 second quarter ended March 31, 2022.
-
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Apr 06, 2022
4/6/2022
Arrowhead Pharmaceuticals, Inc. announced that as an inducement to entering into employment with the Company, on April 1, 2022, the Compensation Committee of the Company’s Board of Directors approved “inducement” grants to 23 new employees under Rule 5635 of the NASDAQ Listing Rules.
-
Arrowhead Pharmaceuticals to Participate in Upcoming April 2022 Conferences
4/1/2022
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events.
-
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases
3/24/2022
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-MUC5AC.
-
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma
3/15/2022
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-RAGE.
-
Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia
2/24/2022
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has reached full planned enrollment of more than 180 participants in the Phase 2b ARCHES-2 clinical study of ARO-ANG3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with mixed dyslipidemia.
-
Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
2/18/2022
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in AROC3-1001, a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi).
-
Arrowhead Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022
2/17/2022
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced positive interim results from AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with clear cell renal cell carcinoma (ccRCC).
-
Arrowhead Pharmaceuticals Reports Fiscal 2022 First Quarter Results
2/2/2022
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal first quarter ended December 31, 2021.
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 First Quarter Results
1/21/2022
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 2, 2022, at 4:30 p.m. ET to discuss its financial results for the fiscal 2022 first quarter ended December 31, 2021.
-
Clinical Catch-Up: January 10-14
1/17/2022
Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look. -
Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
1/12/2022
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patients in the PALISADE study, a Phase 3 clinical study to evaluate the efficacy and safety of ARO-APOC3 in adults with familial chylomicronemia syndrome (FCS).
-
Arrowhead Initiates Project to Build New Manufacturing and Lab Facilities
12/20/2021
Arrowhead Pharmaceuticals, Inc. announced that it has completed a transaction to purchase 13 acres of land in the Verona Technology Park in Verona, WI, which is planned to be the site of an approximately 140,000 square foot drug manufacturing facility and an approximately 115,000 square foot laboratory and office facility to support process development and analytical activities.